We would love to hear your thoughts about our site and services, please take our survey here.
Excellent interview with Geremy...https://www.youtube.com/watch?v=EcHd_35vjf4&t=778s
Sativa Wellness Group Inc.
("Sativa Wellness Group", or the "Company")
Record Week
Sativa Wellness Group announces record week, over 140 clinics and £13.8m revenue.
Sativa Wellness Group is pleased to announce that last week was the Company's best week to date for bookings, with several days exceeding previous records. This meant the company exceeded £13.8m revenue in the eleven months to the end of November.
There are now over 140 clinics in the Goodbody network, including Superdrug supporting clinics. Goodbody clinics will continue to roll out blood testing while responding to the government's latest guidance for the new COVID-19 Omicron variant. All travellers will now have to have a PCR test two days after they return to the UK and our clinics are available to book online at Private Covid Testing England & Wales (goodbodyclinic.com) .
Geremy Thomas, Executive Chairman, said; "We are pleased to be able to support the return of PCR testing as the gold standard of COVID detection and trust that this in combination with vaccinations will control this new variant of the virus. We are delighted that we have now achieved over £13m revenue while meeting this essential need."
In light of Sativas relationship with Lexamed this is interesting news... https://businesscann.com/a-traffic-light-german-coalition-looks-set-to-give-the-green-light-to-europes-first-adult-use-cannabis-market/
https://www.meshholdings.net/wp-content/uploads/MESH-UPDATE-ON-SANCTIONING-OF-THE-SCHEME-20211112.pdf
ttps://www.meshholdings.net/wp-content/uploads/Mesh-Holdings-Plc-Consolidate-Financial-Statement-FY2021.pdf
Interesting article by Alisdaire Haynes of AQUIS....
https://www.aquis.eu/why-its-cannabis-stocks-time-shine
Good news DJ thanks for posting. Also the full 75 page announcement is here: https://www.meshholdings.net/wp-content/uploads/MESH-AAA-Scheme-Document.pdf
23 July 2021
Sativa Wellness announces Strong position and Clear Strategy
Sativa Wellness is pleased to announce its new business strategy following a strong start to the year.
Highlights for first half of 2021
· Change in leadership with the founder returning as Chair and a strong top team appointed.
· The Wellness business aligned in three clear divisions as CBD products, Cannabinoid testing and Clinic Testing Services each with a clear business head.
· Q1 the best quarterly turnover to date for any quarter since Sativa Wellness and its predecessor Sativa Group Plc started in 2018 at £1.37m.
· Q2 produced even stronger revenue results with full results for the first 6 months to be reported in August.
· The business is operating on a positive cash flow, and is maintaining a healthy cash position to further its acquisition strategy.
· The main trading company Goodbody Botanicals has generated profits year to date in 2021, from a loss-making position in previous years.
· The novel food submission submitted on time, full acceptance is still in progress.
· ISO 17025 achieved by the Phytovista Laboratory for cannabinoid testing.
· Roll out of 47 COVID testing clinics to build the newest division of the business.
· Successful placement to invest in the future business.
Strategic direction
The business will align the legal entities within the Group with the divisions as laid out above separating clinic testing from CBD so clearer reporting will be available in 2022. The plans we have in place and are progressing include:
CBD Products-Goodbody Brand
· Secure sales through well-known online platforms.
· Build a 'membership' model for CBD to build predictable revenues.
· Extent product range to include drinks and vape.
· Secure distribution agreements with partners throughout Europe.
· Progress merger and acquisitions to increase the product range and revenue.
· Expand the production of an increased range in Poland.
Cannabinoid Testing
· Expanding the scope of the ISO17025 accreditation.
· Work with the Polish laboratory team to expand cannabinoid testing in Europe.
· Position the business to partner with institutions as a key supplier.
Clinic Services
· Significantly increase the footprint of clinics across the UK.
· Expand COVID 19 testing, incorporating Influenza A&B and RSV.
· Introduce a range of wellness testing through the clinic network.
· Introduce technical solutions for faster testing.
· Introduce corporate testing.
Geremy Thomas, Executive Chairman, says; "It has been six months since I felt compelled to take back leadership of Sativa and I am pleased to say the changes made have produced strong results both financially and operationally. The next phase will be exciting for us all."
Marc Howells, Chief Executive Officer, says "I am delighted to join such an exciting Company
Sounds positive... https://twitter.com/AnandaPlc/status/1402528542194274309
Looks positive.... https://www.aquis.eu/aquis-stock-exchange/member?securityidaqse=SWEL
Been in Mesh from way back when it was High Growth Capital so hope this latest info is good news at last. As I understand it AAA have shares in AAQA & Mesh. AAA are listed on AIM at around 39p (which is about what Mesh shares were at when suspended). Anybody have any thoughts how this might affect Mesh when relisted? Are we better off in AAA? Good luck all
Good news....??
https://www.meshholdings.net/wp-content/uploads/20210215-MESH-Holdings-Sentiance-SPA.pdf
According to their latest newsletter (extracted yesterday) 'The Home Office has advised DJT Plants that its application has progressed successfully through internal Home Office checks and that at this point no objections have been raised. The Home Office has also advised DJT Plants that a site visit and meeting with DJT Plants’ personnel is necessary prior to licence issuance. However, due to the COVID-19 situation the Home Office is currently unable to make such a visit. It has undertaken to conduct its visit as soon as its travel restrictions allow.
The Directors remain positive and confident that the Company is well placed to provide UK grown and manufactured cannabis flower and oil products to UK based patients and, in due course, to international markets.